Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.6× iShares 3 7 Year Treasury Bond ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IEI | VRTX | |
|---|---|---|
Market Cap | $16.72B | $127.55B |
Volume | 3,963,319 | 1,487,944 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $557.96 |
52-Week Low | $113.17 | $407.37 |
Typical Hold Time | 43 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.49 with minimal daily movement, up 0.1%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent corporate actions include consistent dividend payments. The bond market environment, highlighted by rising Treasury yields, influences sentiment, with news pointing to volatility in interest rates affecting fixed-income related assets.
The outlook remains cautious due to bearish technical signals and macroeconomic pressures from rising yields. Investment opportunities include dividend consistency, but risks involve interest rate sensitivity and market volatility. A neutral to bearish stance is warranted pending clearer fundamental data or stabilization in bond markets.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
